Supplementary Table 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring &lt;i&gt;HRR&lt;/i&gt; Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial